Mobile

A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3 WAY CROSS-OVER STUDY TO EVALUATE THE EFFECT ON TROUGH FEV1 AFTER 4 WEEKS TREATMENT WITH CHF 5188 pMDI QD (FIXED COMBINATION BUDESONIDE / CARMOTEROL) IN...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013759-32

A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3 WAY CROSS-OVER STUDY TO EVALUATE THE EFFECT ON TROUGH FEV1 AFTER 4 WEEKS TREATMENT WITH CHF 5188 pMDI QD (FIXED COMBINATION BUDESONIDE / CARMOTEROL) IN ADULT PATIENTS WITH MODERATE OR SEVERE PERSISTENT ASTHMA

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate superiority of CHF5188 pMDI 400/4µg administered once-a-day in the morning over budesonide extrafine pMDI on trough FEV1 after 4 weeks of treatment in persistent moderate or severe asthmatic patients partly controlled with ICS or ICS/LABA.

Critère d'inclusion

  • Moderate or Severe Persistent Asthma

Liens